A real-world study in Galicia showed nirsevimab reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second. The RSV prevention market is expanding to cover high-risk children, with Beyfortus the only antibody approved for second-season use. The FDA has cited Sanofi for misleading promotional claims about the product.
Long-term data from ASCO 2026 shows the personalized cancer vaccine Intismeran Autogene, combined with Keytruda, reduces recurrence or death risk by 49% in high-risk melanoma patients. Developed by MSD and Moderna, the vaccine uses AI to select neoantigens from a patient's tumor and mRNA technology to create a personalized treatment. The results signal a major advance for a field that had struggled for decades, spurring similar development efforts by other companies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07726901 |
Empirical Anatomy-Based Ablation vs Emphasize Map-Guided Substrate Ablation in Persistent Atrial Fibrillation : (COMPASS-AF) |
RECRUITING | NA |
| NCT07634666 |
Prediction of Myocardial Injury After Non-Cardiac Surgery in Urologic Cancer Patients |
RECRUITING | |
| NCT07631156 |
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure |
NOT_YET_RECRUITING | PHASE4 |
| NCT06929897 |
PVI Alone vs PVI With Posterior Wall Isolation for Pulse-Field Ablation in Persistent AF |
ENROLLING_BY_INVITATION | NA |
| NCT06786039 |
Clinical Impact of Non-invasive Neurally Adjusted Ventilatory Assist in Very Preterm Infants |
RECRUITING | |
| NCT06643572 |
Comparing of Using Patient Imaging and Virtual Reality-based Simulation Prior to Lumbar Transforaminal Injections |
COMPLETED | NA |
| NCT06184009 |
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia |
RECRUITING | PHASE2 |
| NCT06099366 |
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children |
RECRUITING | PHASE2 |
| NCT04284943 |
Surgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery |
RECRUITING | NA |
